[单项选择]1)People with diabetes have too much sugar in their blood, so a drug that lowers blood sugar ought to be a good treatment, right
2) Maybe not. Consider the diabetes drug Avandia, or rosiglitazone, which was approved in 1999．it lowers blood sugar, and about a million people in the United States have been talking it for Type 2 diabetes, the most common form of the disease. But last week, doctors reported that Avandia might increase the risk of heart attacks.
3) Heart disease is a major complication of diabetes, so a drug that could make the risk even worse is bad news indeed.
4) The jury is still out on Avandia. Meanwhile, patient advocates and some politicians and researchers are already denouncing it, and the Food and Drug Administration has issued a tepid "safety alert" telling patients to ask their doctors what to do while the agency "is carefully weighing several complex sources of data." Avandia’s manufacturer, GlaxoSmithKline, insists it is safe. Personal injury
A. Surrogate endpoints are more reliable because they are based on objective measures.
B. Surrogate endpoints are not always reliable because the disease being treated may be too complicated to gauge with just one tool.
C. Surrogate endpoints may help streamline the process of drug approval.
D. Surrogate endpoints do not always reflect the safety of a drug because it may have many more effects than the one being measured.